Mariana M Cajaiba1, Lisa M Dyer2, James I Geller3, Lawrence J Jennings1, David George1, Dawn Kirschmann1, Stephen M Rohan4, Nicholas G Cost5, Geetika Khanna6, Elizabeth A Mullen7, Jeffrey S Dome8, Conrad V Fernandez9, Elizabeth J Perlman1. 1. Department of Pathology and Laboratory Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago,`, Chicago, Illinois. 2. Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 3. Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 4. Department of Pathology, Colorado Pathology Consultants, Denver, Colorado. 5. Department of Surgery, University of Colorado, Denver, Colorado. 6. Department of Radiology, Washington University School of Medicine, St Louis, Missouri. 7. Department of Pediatric Oncology, Children's Hospital, Boston, Massachusetts. 8. Division of Oncology, Children's National Medical Center, Washington, District of Columbia. 9. IWK Health Center, Dalhousie University, Halifax, Nova Scotia, Canada.
Abstract
BACKGROUND: Renal cell carcinomas (RCCs) are rare in young patients. Knowledge of their pathologic and molecular spectrum remains limited, and no prospective studies have been performed to date in this population. This study analyzes patients diagnosed with RCC who were prospectively enrolled in the AREN03B2 Children's Oncology Group (COG). The objective was to classify these tumors with the aid of focused genetic testing and to characterize their features. METHODS: All tumors registered as RCC by central review were retrospectively re-reviewed and underwent additional ancillary studies. Tumors were classified according to the 2016 World Health Organization classification system when possible. RESULTS: In total, 212 tumors were identified, and these were classified as microphthalmia transcription factor (MiT) translocation RCC (MiT-RCC) (41.5%), papillary RCC (16.5%), renal medullary carcinoma (12.3%), chromophobe RCC (6.6%), clear cell RCC (3.3%), fumarate hydratase-deficient RCC (1.4%), and succinate dehydrogenase-deficient RCC (0.5%). Other subtypes included tuberous sclerosis-associated RCC (4.2%), anaplastic lymphoma kinase (ALK)-rearranged RCC (3.8%), thyroid-like RCC (1.4%), myoepithelial carcinoma (0.9%), and unclassified (7.5%). MiT-RCCs were classified as either transcription factor E3 (TFE3) (93.2%) or EB (TFEB) (6.8%) translocations, and characterization of fusion partners was possible in most tumors. CONCLUSIONS: The current study delineates the frequency of distinct RCC subtypes in a large prospective series of young patients and contributes knowledge to the diagnostic, clinical, and genetic features of MiT-RCC, the most common subtype among this age group. The identification of rare subtypes expands the spectrum of RCC in young patients, supporting the need for a thorough diagnostic workup. These studies may aid in the introduction of specific therapies for different RCC subtypes in the future. Cancer 2018.
BACKGROUND:Renal cell carcinomas (RCCs) are rare in young patients. Knowledge of their pathologic and molecular spectrum remains limited, and no prospective studies have been performed to date in this population. This study analyzes patients diagnosed with RCC who were prospectively enrolled in the AREN03B2 Children's Oncology Group (COG). The objective was to classify these tumors with the aid of focused genetic testing and to characterize their features. METHODS: All tumors registered as RCC by central review were retrospectively re-reviewed and underwent additional ancillary studies. Tumors were classified according to the 2016 World Health Organization classification system when possible. RESULTS: In total, 212 tumors were identified, and these were classified as microphthalmia transcription factor (MiT) translocation RCC (MiT-RCC) (41.5%), papillary RCC (16.5%), renal medullary carcinoma (12.3%), chromophobe RCC (6.6%), clear cell RCC (3.3%), fumarate hydratase-deficient RCC (1.4%), and succinate dehydrogenase-deficient RCC (0.5%). Other subtypes included tuberous sclerosis-associated RCC (4.2%), anaplastic lymphoma kinase (ALK)-rearranged RCC (3.8%), thyroid-like RCC (1.4%), myoepithelial carcinoma (0.9%), and unclassified (7.5%). MiT-RCCs were classified as either transcription factor E3 (TFE3) (93.2%) or EB (TFEB) (6.8%) translocations, and characterization of fusion partners was possible in most tumors. CONCLUSIONS: The current study delineates the frequency of distinct RCC subtypes in a large prospective series of young patients and contributes knowledge to the diagnostic, clinical, and genetic features of MiT-RCC, the most common subtype among this age group. The identification of rare subtypes expands the spectrum of RCC in young patients, supporting the need for a thorough diagnostic workup. These studies may aid in the introduction of specific therapies for different RCC subtypes in the future. Cancer 2018.
Authors: Pedram Argani; Raluca Yonescu; Laura Morsberger; Kerry Morris; George J Netto; Nathan Smith; Nilda Gonzalez; Peter B Illei; Marc Ladanyi; Constance A Griffin Journal: Am J Surg Pathol Date: 2012-10 Impact factor: 6.394
Authors: Elisabeth Bruder; Oliver Passera; Dieter Harms; Ivo Leuschner; Marc Ladanyi; Pedram Argani; John N Eble; Kirsten Struckmann; Peter Schraml; Holger Moch Journal: Am J Surg Pathol Date: 2004-09 Impact factor: 6.394
Authors: Pedram Argani; Minghao Zhong; Victor E Reuter; John T Fallon; Jonathan I Epstein; George J Netto; Cristina R Antonescu Journal: Am J Surg Pathol Date: 2016-06 Impact factor: 6.394
Authors: Mariana M Cajaiba; Lawrence J Jennings; David George; Elizabeth J Perlman Journal: Genes Chromosomes Cancer Date: 2016-07-07 Impact factor: 5.006
Authors: Ping Yang; Kristine M Cornejo; Peter M Sadow; Liang Cheng; Mingsheng Wang; Yu Xiao; Zhong Jiang; Esther Oliva; Sergiusz Jozwiak; Robert L Nussbaum; Adam S Feldman; Elahna Paul; Elizabeth A Thiele; Jane J Yu; Elizabeth P Henske; David J Kwiatkowski; Robert H Young; Chin-Lee Wu Journal: Am J Surg Pathol Date: 2014-07 Impact factor: 6.394
Authors: Sounak Gupta; Pedram Argani; Achim A Jungbluth; Ying-Bei Chen; Satish K Tickoo; Samson W Fine; Anuradha Gopalan; Hikmat A Al-Ahmadie; Sahussapont J Sirintrapun; Alejandro Sanchez; Abraham Ari Hakimi; Tiffany Mcfarlane; Paulo A Salazar; Sean R Williamson; Stephanie L Skala; Rohit Mehra; Ondrej Hes; Cristina R Antonescu; Marc Ladanyi; Maria E Arcila; Victor E Reuter Journal: Am J Surg Pathol Date: 2019-11 Impact factor: 6.394
Authors: James I Geller; Nicholas G Cost; Yueh-Yun Chi; Brett Tornwall; Mariana Cajaiba; Elizabeth J Perlman; Yeonil Kim; Elizabeth A Mullen; Richard D Glick; Geetika Khanna; Najat C Daw; Peter Ehrlich; Conrad V Fernandez; Jeffrey S Dome Journal: Cancer Date: 2020-09-14 Impact factor: 6.860
Authors: Renzo G DiNatale; Alejandro Sanchez; A Ari Hakimi; Ed Reznik; Julian Marcon; Ritesh R Kotecha; Sounak Gupta; Fengshen Kuo; Vladimir Makarov; Amar Sandhu; Roy Mano; Andrew W Silagy; Kyle A Blum; Daniel E Nassau; Nicole E Benfante; Michael V Ortiz; Maria I Carlo; Timothy A Chan; Robert J Motzer; Martin H Voss; Jonathan Coleman; Paul Russo; Victor Reuter Journal: Clin Cancer Res Date: 2020-03-27 Impact factor: 12.531
Authors: Pavlos Msaouel; Gabriel G Malouf; Xiaoping Su; Hui Yao; Durga N Tripathi; Melinda Soeung; Jianjun Gao; Priya Rao; Cristian Coarfa; Chad J Creighton; Jean-Philippe Bertocchio; Selvi Kunnimalaiyaan; Asha S Multani; Jorge Blando; Rong He; Daniel D Shapiro; Luigi Perelli; Sanjana Srinivasan; Federica Carbone; Patrick G Pilié; Menuka Karki; Riyad N H Seervai; Bujamin H Vokshi; Dolores Lopez-Terrada; Emily H Cheng; Ximing Tang; Wei Lu; Ignacio I Wistuba; Timothy C Thompson; Irwin Davidson; Virginia Giuliani; Katharina Schlacher; Alessandro Carugo; Timothy P Heffernan; Padmanee Sharma; Jose A Karam; Christopher G Wood; Cheryl L Walker; Giannicola Genovese; Nizar M Tannir Journal: Cancer Cell Date: 2020-04-30 Impact factor: 31.743
Authors: Martin Lang; Cathy D Vocke; Christopher J Ricketts; Adam R Metwalli; Mark W Ball; Laura S Schmidt; William M Linehan Journal: Urology Date: 2020-11-24 Impact factor: 2.649
Authors: J A Hol; M C J Jongmans; A S Littooij; R R de Krijger; R P Kuiper; J J T van Harssel; A Mensenkamp; M Simons; G A M Tytgat; M M van den Heuvel-Eibrink; M van Grotel Journal: Fam Cancer Date: 2020-01 Impact factor: 2.375